San Diego, CA-based Cytori Therapeutics is using Medistem’s patented “Stem Cell Mediated Treg Activation” technology to develop autoimmune disease treatments.
Under the terms of the agreement, Cytori gains a license and exclusive rights to use Medistem technology outlined in U.S. Patent No. 8,241,621. Cytori will use Medistem technology in efforts related to its Adipose-Derived Regenerative Cell-based platform for the treatment of autoimmune diseases. Financial terms were not disclosed.
“We are delighted to have formalized a licensing agreement with an adult stem cell leader like Cytori and look forward to working with them in the future,” Medistem CEO Alan J. Lewis, Ph.D., said in a statement.
Added Cytori’s Marc H. Hedrick, president: “We are pleased to have licensed this patent from Medistem because it strengthens our patent portfolio in the area of immune disease.”